As of Dec 8, 2018 Arbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Declined Their Shorts By 31.2%

Arbutus Biopharma Corporation (NASDAQ:ABUS) Corporate Logo

Arbutus Biopharma Corporation (NASDAQ:ABUS) had a decrease of its short interest by 31.2%. FINRA announced in December ABUS’s total 1.68 million short interest. The 2.45 million previous shares are down with 31.2%. 9 days will cost ABUS with 181,100 average volume to restore its former position. Arbutus Biopharma Corporation’s short interest float is 5.4%.

The stock decreased 3.93% or $0.18 during the last trading session, touching $4.4.Currently Arbutus Biopharma Corporation is uptrending after 119.54% change in last December 8, 2017. ABUS has also 120,184 shares volume. ABUS outperformed the S&P 500 by 103.92%.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States.The firm is valued at $244.20 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).Currently it has negative earnings. The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

For more Arbutus Biopharma Corporation (NASDAQ:ABUS) news published recently go to:,,, or The titles are as follows: “Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun – Seeking Alpha” published on July 18, 2018, “Benzinga’s Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index – Benzinga” on July 05, 2018, “Arbutus Announces Corporate Update and Year-End 2017 Financial Results – GlobeNewswire” with a publish date: March 14, 2018, “Arbutus Biopharma: The Good, The Bad, And The Ugly – Seeking Alpha” and the last “Premarket analyst action – healthcare – Seeking Alpha” with publication date: October 15, 2018.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.